DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years

Recruiting

Conditions: Relapsing Multiple Sclerosis

Interventions: Other: Ofatumumab

First Posted Date: 2023-03-20

Last Posted Date: 2025-01-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT05776888

Locations: 🇦🇹
Novartis Investigative Site, Vienna, Austria

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

Phase 3

Active, not recruiting

Conditions: Polymyalgia Rheumatica

Interventions: Other: Placebo to secukinumab
Drug: Secukinumab 300 mg
Drug: Secukinumab 150 mg

First Posted Date: 2023-03-14

Last Posted Date: 2025-05-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 381

Registration Number: NCT05767034

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom
🇺🇸
Arizona Arthritis and Rheumatology Associates PLLC, Avondale, Arizona, United States
🇺🇸
UF Health Cancer Center, Gainesville, Florida, United States

and more 20 locations

Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants

Phase 2

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: LTP001

First Posted Date: 2023-03-10

Last Posted Date: 2024-08-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT05764265

Locations: 🇬🇧
Novartis Investigative Site, Sheffield, South Yorkshire, United Kingdom
🇺🇸
Pulmonary Associates PA ., Mesa, Arizona, United States

Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Matching Placebo for Inclisiran
Drug: Inclisiran
Drug: Ezetimibe
Drug: Matching Placebo for Ezetimibe

First Posted Date: 2023-03-10

Last Posted Date: 2024-10-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 350

Registration Number: NCT05763875

Locations: 🇺🇸
Southern Clin Research Clinic ., Zachary, Louisiana, United States
🇲🇽
Novartis Investigative Site, Queretaro, Mexico
🇺🇸
Hillcrest Medical Research, DeLand, Florida, United States

and more 6 locations

Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Phase 3

Terminated

Conditions: Rotator Cuff Tendinopathy

Interventions: Drug: Placebo
Drug: Secukinumab

First Posted Date: 2023-03-07

Last Posted Date: 2025-02-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT05758415

Locations: 🇺🇸
Horizon Clinical Research, La Mesa, California, United States
🇺🇸
Medvin Clinical Research, Van Nuys, California, United States
🇺🇸
Conquest Research, Winter Park, Florida, United States

and more 2 locations

A Randomized, Open, Parallel, Controlled, Multi-center, Interventional, Cross-sectional Study to Evaluate the Detection Rate of Psoriatic Arthritis in Korean Moderate-to-severe Psoriasis Patients, With or Without Active Screening for Arthritis in Psoriasis (ASAP Study)

Not Applicable

Completed

Conditions: Psoriasis

Interventions: Diagnostic Test: EARP group
Diagnostic Test: Routine practice group

First Posted Date: 2023-03-07

Last Posted Date: 2025-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 368

Registration Number: NCT05758402

Locations: 🇰🇷
Novartis Investigative Site, Taegu, Korea, Republic of

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

Phase 3

Recruiting

Conditions: IC-MPGN

Interventions: Drug: Placebo
Drug: iptacopan

First Posted Date: 2023-03-06

Last Posted Date: 2025-02-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 106

Registration Number: NCT05755386

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Univ Cali Irvine ALS Neuromuscular, Orange, California, United States

and more 6 locations

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Part 1; LOU064 (Remibrutinib)
Drug: Part 2; LOU064 (Remibrutinib)

First Posted Date: 2023-03-03

Last Posted Date: 2025-05-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 38

Registration Number: NCT05753592

Locations: 🇭🇺
Novartis Investigative Site, Miskolc, Baz, Hungary

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria

Phase 2

Recruiting

Conditions: Uncomplicated Plasmodium Falciparum Malaria

Interventions: Drug: INE963
Drug: KAE609 (Cipargamin)
Drug: SoC (Coartem)
Drug: KLU156

First Posted Date: 2023-03-02

Last Posted Date: 2025-03-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 327

Registration Number: NCT05750628

Locations: 🇺🇬
Novartis Investigative Site, Tororo, Uganda

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Phase 3

Active, not recruiting

Conditions: Primary Prevention of Atherosclerotic Cardiovascular Disease

Interventions: Drug: Placebo in 1.5ml
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

First Posted Date: 2023-02-22

Last Posted Date: 2025-03-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 14013

Registration Number: NCT05739383

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
🇵🇷
Research and Cardiovascular Corp, Ponce, Puerto Rico
🇺🇸
Central Alabama Research, Birmingham, Alabama, United States

and more 244 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy